1. Home
  2. NTR vs ALNY Comparison

NTR vs ALNY Comparison

Compare NTR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutrien Ltd.

NTR

Nutrien Ltd.

HOLD

Current Price

$80.68

Market Cap

35.5B

Sector

Industrials

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$260.10

Market Cap

38.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTR
ALNY
Founded
2017
2002
Country
Canada
United States
Employees
N/A
115
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.5B
38.9B
IPO Year
2018
2004

Fundamental Metrics

Financial Performance
Metric
NTR
ALNY
Price
$80.68
$260.10
Analyst Decision
Buy
Strong Buy
Analyst Count
22
28
Target Price
$75.45
$471.00
AVG Volume (30 Days)
2.4M
1.6M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
2.95%
N/A
EPS Growth
N/A
206.88
EPS
N/A
2.71
Revenue
N/A
$1,037,418,000.00
Revenue This Year
$4.03
$52.67
Revenue Next Year
N/A
$31.48
P/E Ratio
$18.99
$98.20
Revenue Growth
N/A
22.88
52 Week Low
$53.03
$197.81
52 Week High
$85.36
$495.55

Technical Indicators

Market Signals
Indicator
NTR
ALNY
Relative Strength Index (RSI) 74.15 58.55
Support Level $68.97 $223.61
Resistance Level $85.36 $314.04
Average True Range (ATR) 2.11 11.22
MACD 0.78 5.23
Stochastic Oscillator 93.08 78.77

Price Performance

Historical Comparison
NTR
ALNY

About NTR Nutrien Ltd.

Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients—nitrogen, potash, and phosphate—although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: